Review Articles

An overview of ivabradine

Tumelo Ramoleta, Natalie Schellack, Elmien Bronkhorst
South African Family Practice | Vol 58, No 6 : November/December| a4572 | DOI: https://doi.org/10.4102/safp.v58i6.4572 | © 2016 Natalie Schellack | This work is licensed under CC Attribution 4.0
Submitted: 22 September 2016 | Published: 16 December 2016

About the author(s)

Tumelo Ramoleta, Sefako Makgatho Health Sciences University, South Africa
Natalie Schellack, Sefako Makgatho Health Sciences University, South Africa
Elmien Bronkhorst, Sefako Makgatho Health Sciences University, South Africa

Full Text:

PDF (65KB)

Abstract

This article provides an overview of the therapeutic effects of ivabradine in the treatment of coronary artery disease (CAD), and in the management of stable angina pectoris (SAP) and congestive cardiac failure (CCF). Patients with SAP have a reduced quality of life and are unable to work efficiently, resulting in the increased use of healthcare resources. Unlike the other antianginal drugs (i.e. the beta-blockers, calcium-channel blockers and organic nitrates), ivabradine specifically targets the If current of the sinus node. It reduces the frequency of angina attacks and increases the time until symptoms during work appear. Clinical evidence has shown that ivabradine is an effective anti-ischaemic and antianginal agent, comparable to the beta-blockers and calcium-channel antagonist in controlling the symptoms of myocardial ischemia.

Keywords

ivabradine; If current; sinus node; congestive cardiac failure; angina pectoris; antianginal agent

Metrics

Total abstract views: 1806
Total article views: 820


Crossref Citations

No related citations found.